Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F12%3A8290" target="_blank" >RIV/00064203:_____/12:8290 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11130/12:8290
Výsledek na webu
<a href="http://dx.doi.org/10.1038/leu.2011.267" target="_blank" >http://dx.doi.org/10.1038/leu.2011.267</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report
Popis výsledku v původním jazyce
Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and-2004 (n = 66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic-hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125 = 96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66 +/- 4%, and improved from 61 +/- 6% in study-98to 75 +/- 6% in study-2004 (P-logrank 0.14) and event-free survival rates were 44 +/- 6% and 51 +/- 6% (P-logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-<2- or 2-<10-year olds, P-logrank 0
Název v anglickém jazyce
Favorable outcome in infants with AML after intensive first- nd second-line treatment: an AML-BFM study group report
Popis výsledku anglicky
Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and-2004 (n = 66). Treatment regimens of both studies were comparable, consisting of intensive induction followed by four courses (mainly high-dose cytarabine and anthracyclines). Allogeneic-hematopoietic stem-cell-transplantation (allo-HSCT) in 1st remission was optional for high-risk (HR) patients. Most infants (120/125 = 96%) were HR patients according to morphological, cytogenetic/molecular genetic and response criteria. Five-year overall survival was 66 +/- 4%, and improved from 61 +/- 6% in study-98to 75 +/- 6% in study-2004 (P-logrank 0.14) and event-free survival rates were 44 +/- 6% and 51 +/- 6% (P-logrank 0.66), respectively. Results in HR infants were similar to those of older HR children (1-<2- or 2-<10-year olds, P-logrank 0
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Leukemia
ISSN
0887-6924
e-ISSN
—
Svazek periodika
26
Číslo periodika v rámci svazku
4
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
8
Strana od-do
654-661
Kód UT WoS článku
000302788300011
EID výsledku v databázi Scopus
—